104
Participants
Start Date
March 14, 2016
Primary Completion Date
June 16, 2017
Study Completion Date
June 16, 2017
GSK3008356
This intervention is available as 0.5, 1, 5, and 25 mg white oral tablet. The formulation will be used to administer dose of 5 mg, 10 mg, 30 mg, 45 mg, 75 mg, 90 mg, 125 mg, 180 mg, 200 mg, and 250 mg total daily dose during the study.
Placebo
This intervention is available as white oral tablet. The formulation will be used as a matching placebo for GSK3008356 during the study.
GSK Investigational Site, Melbourne
Lead Sponsor
Collaborators (1)
Nucleus Network Ltd
OTHER
GlaxoSmithKline
INDUSTRY